В зоне риска. Тонкости защиты женского организма. Как ВПЧ проникает в наш организм, чем он опасен и что поможет избежать последствий

51. Santesso N., Mustafa R.A., Wiercioch W., Kehar, Gandhi S., Chen Y., Cheung A., Hopkins J., Khatib R., Ma B., Mustafa A.A., Lloyd N., Wu D., Broutet N., Schünemann H.J. Systematic reviews and meta-analyses of benefits and harms of cryotherapy, LEEP, and cold knife conization to treat cervical intraepithelial neoplasia Int J Gynaecol Obstet. 2016 Mar; 132(3):266–71.

52. Ghaem-Maghami S., Sagi S., Majeed G., Soutter W.P. Incomplete excision of cervical intraepithelial neoplasia and risk of treatment failure: a meta-analysis. Lancet Oncol 2007; 8(11):985–93.

53. Armarnik S., Sheiner E., Piura B., Meirovitz M., Zlotnik A., Levy A. Obstetric outcome following cervical conization. Arch Gynecol Obstet 2011; 283(4):765–9.

54. Bevis K.S., Biggio J.R. Cervical conization and the risk of preterm delivery. Am J Obstet Gynecol 2011; 205:19–27.

55. Jin G., LanLan Z., Li C., Dan Z. Pregnancy outcome following loop electrosurgical excision procedure (LEEP) a systematic reviewand meta-analysis. Arch Gynecol Obstet. 2014 Jan; 289(1):85–99.

56. Ozog D.M., Rkein A.M., Fabi S.G., Gold M.H., Goldman M.P., Lowe N.J., Martin G.M., Munavalli G.S. Photodynamic Therapy: A Clinical Consensus Guide. Dermatol Surg. 2016 Jul; 42(7):804–27.

57. Chilakamarthi U., Giribabu L. Photodynamic Therapy: Past, Present and Future. Chem Rec. 2017 Aug; 17(8):775–802.

58. Agostinis P., Berg K., Cengel K.A., Foster T.H., Girotti A.W., Gollnick S.O., Hahn S.M., Hamblin M.R., Juzeniene A., Kessel D., Korbelik M., Moan J., Mroz P., Nowis D., Piette J., Wilson B.C., Golab J. Photodynamic therapy of cancer: an update. CA Cancer J Clin. 2011 Jul-Aug; 61(4):250–81.

59. Tosti G., Iacobone A.D., Preti E.P., Vaccari S., Barisani A., Pennacchioli E., Cantisani C. The Role of Photodynamic Therapy in the Treatment of Vulvar Intraepithelial Neoplasia Biomedicines. 2018 Feb 2; 6(1). pii: E13

60. Fu Y., Bao Y., Hui Y., Gao X., Yang M., Chang J. Topical photodynamic therapy with 5-aminolevulinic acid for cervical high-risk HPV infection Photodiagnosis Photodyn Ther. 2016 Mar; 13:29–33.

61. Choi M.C., Lee C., Kim S.J. Efficacy and safety of photodynamic therapy for cervical intraepithelial neoplasia: a systemic review Photodiagnosis Photodyn Ther. 2014 Dec; 11(4):479–80.

62. Frega A., Sesti F., De Sanctis L., Pacchiarotti A., Votano S., Biamonti A., Sopracordevole F., Scirpa P., Catalano A., Caserta D., Gentile M., Schimberni M., Moscarini M. Pregnancy outcome after loop electrosurgical excision procedure for cervical intraepithelial neoplasia. Int J Gynaecol Obstet. 2013 Aug; 122(2):145–9.

63. Maździarz A. Successful Pregnancy and Delivery Following Selective Use of Photodynamic Therapy in Treatment of the Cervix and Vulva Diseases. Photodiagnosis Photodyn Ther. 2019 Jul 9. pii: S1572–1000(18)30348-X.

64. Hancock G., Hellner K., Dorrell L. Therapeutic HPV vaccines. Best Pract Res Clin Obstet Gynaecol. 2018 Feb; 47:59–72

65. Ley C., Bauer H.M., Reingold A., et al. Determinants of genital human papillomavirus infection in young women. J Natl Cancer Inst 1991; 83:997–1003.

66. Winer R.L., Hughes J.P., Feng Q., et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 2006; 354(25):2645–54.

67. Castle P.E., Maza M. Prophylactic HPV vaccination: past, present, and future. Epidemiol Infect. 2016 Feb; 144(3):449–68.

68. CDC. Human papillomavirus vaccination coverage among adolescent girls, 2007–2012, and postlicensure vaccine safety monitoring, 2006–2. Morbidity and Mortality Weekly Report 2013; 62: 591–595.

69. Gee J., et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine 2011; 29: 8279–8284.

70. Anon. Global Advisory Committee on Vaccine Safety. Statement on the continued safety of HPV vaccination. 2014 (http://www.who.int/vaccine_safety/committee/ topics/hpv/GACVS_Statement_HPV_12_Mar_2014. pdf). Accessed 9 November 2014.

71. Malagon T., et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infectious Diseases 2012; 12: 781–789.

72. Brown D.R., Kjaer S.K., Sigurdsson K., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis 2009; 199:926.

73. Crowe E., et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. British Medical Journal 2014; 348: g1458.

74. Donovan B., et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infectious Diseases 2011; 11: 39–44.